ArticleAmerican journal of physiology. Endocrinology and metabolism2020
Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein.
Article in American journal of physiology. Endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial.Acta anaesthesiologica Scandinavica · 2026Trial
- Immunometabolic Modulation in Obese Asthma: How GLP-1 Receptor Agonists Could Influence Systemic and Pulmonary Immune Phenotypes.Pulmonary therapy · 2026Review
- Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.International journal of molecular sciences · 2026Review
- Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.ERJ open research · 2026Review
- The Anti-Inflammatory Role of GLP-1 RAs in Acute Lung Injury and Acute Respiratory Distress Syndrome.International journal of molecular sciences · 2026Review
- Bronchopulmonary dysplasia induced by hyperoxia attenuated by A GLP-1 analog, Liraglutide, by regulating the ACE-2/Ang(1-7)/Mas receptor pathway.Pediatric research · 2026Article
- GTS-21 Alleviates Acute Lung Injury by Enhancing GLP-1 Secretion and Regulating Alveolar Surfactant Proteins via α7nAChR Activation.Inflammation · 2026Article
- Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.The Journal of clinical investigation · 2025 · on this mapReview
- Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study.International journal of surgery (London, England) · 2025Article
- Therapeutic Effects of TN13 Peptide on Acute Respiratory Distress Syndrome and Sepsis Models In Vivo.Journal of clinical medicine · 2025Article
- Pulmonary outcomes of incretin-based therapies in COPD patients receiving single-inhaler triple therapy.ERJ open research · 2025Article
- The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.Endocrine · 2025Review
- New horizon of the combined BCG vaccine with probiotic and liraglutide in augmenting beta cell survivalHeliyon · 2024Article
- Hepatic function of glucagon-like peptide-1 and its based diabetes drugs.Medical review (2021) · 2024Review
- Obstructive sleep apnea, the NLRP3 inflammasome and the potential effects of incretin therapies.Frontiers in sleep · 2024Review
- The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2023Article
- Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice.Physiological reports · 2023Article
- An update on the role of thioredoxin-interacting protein in diabetic kidney disease: A mini review.Frontiers in medicine · 2023Review
- The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-Therapeutic potential exploration in lung injury.Acta pharmaceutica Sinica. B · 2022Review
- Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers.International journal of clinical practice · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Repurposing clinically used drugs is among the important strategies in drug discovery. Glucagon-like peptide-1 (GLP-1) and its diabetes-based drugs, such as liraglutide, possess a spectrum of extra-pancreatic functions, while GLP-1 receptor (GLP-1R) is most abundantly expressed in the lung. Recent studies have suggested that GLP-1-based drugs exert beneficial effects in chronic, as well as acute, lung injury rodent models. Here, we show that liraglutide pretreatment reduced LPS induced acute lung injury in mice. It significantly reduced lung injury score, wet/dry lung weight ratio, bronchoalveolar lavage fluid immune cell count and protein concentration, and cell apoptosis in the lung, and it was associated with reduced lung inflammatory cytokine and chemokine gene expression. Importantly, these effects were virtually absent in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.